24h-response to bevacizumab erlortinib in non-small cell lung cancer from blood-based exon array profiling
Homo sapiens
86 Downloadable Samples
Affymetrix Human Human Exon 1.0 ST Array (huex10st)
Submitter Supplied Information
Description
The mechanisms of action of the combined targeted therapy bevacizumab erlotinib in late stage non-squamous non-small cell lung cancer was investigated by means of whole genome exon arrays.